Home > Compound List > Product Information
Verapamil_Molecular_structure_CAS_52-53-9)
Click picture or here to close

Verapamil

Catalog No. DB00661 Name DrugBank
CAS Number 52-53-9 Website http://www.ualberta.ca/
M. F. C27H38N2O4 Telephone (780) 492-3111
M. W. 454.60162 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 543

SYNONYMS

IUPAC name
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
IUPAC Traditional name
verapamil
Brand Name
Univer
Apo-Verap
Verexamil
Geangin
Berkatens
Cardiagutt
Cardibeltin
Dignover
Isoptimo
Isoptin
Isoptin SR
Securon
Veramex
Arpamyl
Calan
Calan SR
Cordilox
Covera-HS
Dilacoran
Drosteakard
Iproveratril
Novo-Veramil
NU-Verap
Quasar
Vasolan
Veracim
Veraptin
Verelan
Verelan PM
Synonyms
Verapamil HCl
Verapamilo [INN-Spanish]
Verapamilum [INN-Latin]
Verapamil [Usan:Ban:Inn]

DATABASE IDS

PubChem CID 2520
CAS Number 52-53-9
PubChem SID 46508158

PROPERTIES

Hydrophobicity(logP) 4.7
Solubility 4.47 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description A calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]
Indication For the treatment of hypertension, angina, and cluster headache prophylaxis.
Pharmacology Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.
Toxicity LD50=8 mg/kg (i.v. in mice)
Affected Organisms
Humans and other mammals
Absorption 90%
Half Life 2.8-7.4 hours
Protein Binding 90%
Elimination Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.
References
Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

  • Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. Pubmed